In summary, we have uncovered a new therapeutic strategy for targeting neutrophil and macrophage infiltration in TACE therapy for HCC via inhibition of the CCL2/CCR2 and CXCLs/CXCR2 axes. This evidence concerns the gene CCL2 and hepatocellular carcinoma.